Cargando…

Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Detalles Bibliográficos
Autores principales:	Sasaki, Yasutsuna, Hamada, Kazuyuki, Kaneta, Toshikado, Takahashi, Takehiro, Kubota, Yutaro, Ishida, Hiroo, Ichikawa, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556401/ https://www.ncbi.nlm.nih.gov/pubmed/26268893 http://dx.doi.org/10.1111/cas.12708

Ejemplares similares

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015)

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
por: Satoh, Etsuko, et al.
Publicado: (2018)

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
por: Kaga, Yasuhiro, et al.
Publicado: (2016)

Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients
por: Katayama, Koki, et al.
Publicado: (2021)

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan
por: Takata, Kosuke, et al.
Publicado: (2016)

Gas-filled Cavities in the Liver
por: Hamada, Kazuyuki, et al.
Publicado: (2018)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022)

Evaluation of Cyclophosphamide Dosage Schedules in Breast Cancer
por: Stoll, B. A.
Publicado: (1970)

Associations of HLA‐C*01:02 and HLA‐B*46:01 with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer
por: Fujita, Ken‐ichi, et al.
Publicado: (2023)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Mifepristone in Fibroids: Comparative Study of Safety and Efficacy of Biweekly Dosage Vs Daily Dosage Schedule
por: Shaikh, Neelofar, et al.
Publicado: (2021)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
por: Segaert, Siegfried
Publicado: (2009)

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
por: Foschini, Francesca, et al.
Publicado: (2020)

Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment
por: Peng, Wencheng, et al.
Publicado: (2023)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer
por: Jain, Neeraj, et al.
Publicado: (2022)

X-Rays: Their Origin, Dosage, and Practical Application
Publicado: (1924)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

Dosage and Dose Schedule Screening of Drug Combinations in Agent-Based Models Reveals Hidden Synergies
por: Barros de Andrade e Sousa, Lisa C., et al.
Publicado: (2016)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
por: Ballestrero, A., et al.
Publicado: (1997)

Effective Dosage and Administration Schedule of Oral Alendronate for Non-nociceptive Symptoms in Rats with Chronic Constriction Injury
por: Im, Sun, et al.
Publicado: (2010)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
por: Lamarca, Angela, et al.
Publicado: (2020)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4j370okp03imr6ifku09l6rogv